Data for the use of metformin and topiramate in the treatment and prevention of second-generation antipsychotic-induced weight gain are limited. Both may be effective in helping patients lose weight via mechanisms that have yet to be clearly defined. The use of metformin results in greater weight loss than topiramate, and topiramate is associated with more risks and may compromise the treatment of schizophrenia. Treatment of antipsychotic-induced weight gain with metformin may be an option after lifestyle and dietary changes have failed.

A majority of biologics approved in the past 15 years include some pediatric information in their labeling, and pediatric trials have been registered for a substantial majority of these products.

Leadership succession planning is crucial to the continuity of the comprehensive vision of the hospital pharmacy department. Leadership development is arguably the main component of training and preparing pharmacists to assume managerial positions. Succession planning begins with a review of the organizational chart in the context of the institution's strategic plan. Then career ladders are developed and key positions that require succession plans are identified. Employee profiles and talent inventory should be performed for all employees to identify education, talent, and experience, as well as areas that need improvement. Employees should set objective goals that align with the department's strategic plan, and management should work collaboratively with employees on how to achieve their goals within a certain timeframe. The succession planning process is dynamic and evolving, and periodic assessments should be conducted to determine how improvements can be made. Succession planning can serve as a marker for the success of hospital pharmacy departments.

± 3.35, which is considered to be within a normal range. If this study is removed, it would appear that all of the studies reviewed would support topiramate's use for attenuation and prevention of antipsychotic-induced weight gain. Indeed, we would argue that the body of clinical evidence is more consistently positive for topiramate than for metformin. At the same time, we agree with Ellinger and colleagues that the safety profile of metformin appears to be more favorable compared to that of topiramate. Finally, we also advocate for larger, controlled studies to assess the beneficial effects of topiramate and metformin on the prevention and attenuation of antipsychotic-induced metabolic aberrations.